Epidemiologic studies have documented a 40–50% reduction in incidence of colorectal
cancer in individuals taking nonsteroidal antiinflammatory drugs (NSAIDs). Since NSAIDs …

Population-based studies have established that long-term intake of non-steroidal anti-
inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of …

The cyclooxygenase (COX) enzymes (COX-1 and COX-2) are key enzymes of prostaglandin
(PG) biosynthesis. Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the …

Abstract Cyclooxygenase-2 (COX-2) is an inducible enzyme that regulates prostaglandin
synthesis and is overexpressed at sites of inflammation and in several epithelial cancers …

Cyclooxygenase (COX), a key enzyme in the prostanoid biosynthetic pathway, has received
considerable attention due to its role in human cancers. Observational and randomized …

Abstract Background/Aims: Several clinical, epidemiological, and animal studies indicate
that nonsteroidal anti-inflammatory drugs (NSAIDs) may alter the incidence of colorectal …

Despite recent improvements in chemotherapy and radiation therapy in cancer management
with the addition of biological agents, novel treatment approaches are needed to further …

Cyclooxygenase (COX), the key regulatory enzyme for prostaglandin synthesis, is
transcribed from two distinct genes. COX-1 is expressed constitutively in most tissues …

Abstract Selective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the
anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory …

Compelling experimental and clinical evidence supports the notion that cyclooxygenase-2,
the inducible isoform of cyclooxygenase, plays a crucial role in oncogenesis. Clinical and …